Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.71 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.71 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.58 |
| ▸ | KDM5C | P41229 | 1/20 | 0.57 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.57 |
| ▸ | CHRM3 | P20309 | 13/20 | 0.56 |
| ▸ | KDM1A | O60341 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28744419 | 0.98 | CYP2D6 (0.73) | CYP2D6CYP2C9HIF1ASIGMAR1KDM5C | |
| SCHEMBL21043985 | 0.91 | CYP2D6 (0.63) | CYP2D6CYP2C9HIF1ASIGMAR1KDM5C | |
| SCHEMBL30218441 | 0.91 | CYP2D6 (0.63) | CYP2D6CYP2C9HIF1ASIGMAR1KDM5C | |
| SCHEMBL4176561 | 0.85 | SLC6A4 (0.58) | CYP2D6CYP2C9HIF1ASIGMAR1CHRM3 | |
| SCHEMBL30799020 | 0.85 | SLC6A4 (0.58) | CYP2D6CYP2C9HIF1ASIGMAR1CHRM3 | |
| SCHEMBL7037977 | 0.85 | CHRM3 (0.69) | CYP2D6CYP2C9HIF1ASIGMAR1CHRM3 | |
| SCHEMBL11369241 | 0.84 | CYP2D6 (0.97) | CYP2D6CYP2C9HIF1AKDM1AKDM4E | |
| SCHEMBL29631127 | 0.84 | CYP2D6 (0.97) | CYP2D6CYP2C9HIF1AKDM1AKDM4E | |
| SCHEMBL8341206 | 0.83 | CYP2D6 (1.00) | CYP2D6CYP2C9HIF1AKDM1A | |
| Hydrochloric Acid SCHEMBL1371448 | 0.83 | CYP2D6 (0.94) | CYP2D6CYP2C9HIF1AKDM1AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9217009-B2 | Version of FDG detectable by single-photon emission computed tomography | MALLINCKRODT LLC (US) | 2015-12-22 | — | — | US | disclosed |
| US-9217009-B2 | Version of FDG detectable by single-photon emission computed tomography | MALLINCKRODT LLC (US) | 2015-12-22 | — | — | US | disclosed |
| US-20140378677-A1 | VERSION OF FDG DETECTABLE BY SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY | MALLINCKRODT VETERINARY, INC. | 2014-12-25 | — | — | US | disclosed |
| US-20140378677-A1 | VERSION OF FDG DETECTABLE BY SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY | MALLINCKRODT VETERINARY, INC. | 2014-12-25 | — | — | US | disclosed |
| US-8858916-B2 | Metal chelate linked to a hexose carrier for use as a metallopharmaceutical diagnostic or therapeutic agent | MALLINCKRODT LLC (US) | 2014-10-14 | — | — | US | disclosed |
| US-8858916-B2 | Metal chelate linked to a hexose carrier for use as a metallopharmaceutical diagnostic or therapeutic agent | MALLINCKRODT LLC (US) | 2014-10-14 | — | — | US | disclosed |
| US-20110177004-A1 | Version of FDG Detectable by Single-Photon Emission Computed Tomography | OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.) | 2011-07-21 | — | — | US | disclosed |
| US-20110177004-A1 | Version of FDG Detectable by Single-Photon Emission Computed Tomography | OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110177004-A1 | Version of FDG Detectable by Single-Photon Emission Computed Tomography | SLC2A1, SLC2A4, SLC2A3 | CYP2D6 1214/4885CYP2C9 3642/4885HIF1A 343/4885 |
| US-20140378677-A1 | VERSION OF FDG DETECTABLE BY SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY | SLC2A1, SLC2A4, SLC2A3 | CYP2D6 1214/4885CYP2C9 3642/4885HIF1A 343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.